While surgical resection remains the mainstay of treatment for localized melanoma, modern therapeutics with demonstrated efficacy in the metastatic setting, including immune checkpoint inhibitors and targeted therapy (BRAF and MEK inhibitors), have quickly made their way to the adjuvant setting for high-risk melanoma. The gene discussed is BRAF; the disease is melanoma.